Tear Sheet

Company Overview

HTG’s mission is to advance the promise of precision medicine through innovative transcriptome-wide profiling technology designed to accelerate the development of diagnostics and hasten the discovery of novel drug candidates to effect lifechanging outcomes. Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. 

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary Don Hardison Joins the Board of Directors for HTG Molecular Diagnostics
TUCSON, Ariz. , May 03, 2016 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that Donnie (Don) M. Hardison has been appointed to its Board of Directors (“Board”).
Toggle Summary Dr. Ann Hanham Joins HTG Molecular Diagnostics’ Board of Directors
TUCSON, Ariz. , Aug. 29, 2016 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that Ann F. Hanham , Ph.D. has been appointed to its Board of Directors (“Board”).
Toggle Summary HTG Adds Three New Distributors in Europe, Expanding and Strengthening Reach in the Nordics and Eastern Europe
TUCSON, Ariz. , June 11, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the signing of three new European distributor agreements to promote HTG products and services in Nordic and
Toggle Summary HTG and Icahn School of Medicine at Mount Sinai Announce Bladder Cancer Research Collaboration
HTG’s Innovative Transcriptome Panel Technology to be Leveraged in Retrospective Studies TUCSON, Ariz. , Nov. 17, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling
Toggle Summary HTG and MD Anderson Cancer Center Enter Into a Sponsored Research Agreement to Investigate New Molecular Diagnostics for Lung Cancer Using HTG's Next-Generation Sequencing Solution for Gene Expression
TUCSON, Ariz. , June 1, 2015 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications and The University of Texas MD Anderson Cancer Center have entered into a 2-year Sponsored Research Agreement to support

Stock Chart

SEC Filings

Filing date Description

Report of unscheduled material events or corporate event

An amendment to the SC 13G filing

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities